pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
the cabinet
Drugs
8,127
products tracked
★ save view
↓
export CSV
search
phase
all
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
sort
catalysts
recent
name
therapeutic area
all
Oncology
1831
Infectious Disease
718
Cardiology
425
Pulmonology
396
Immunology
371
Ophthalmology
368
Dermatology
300
Women's Health
131
view
list
cards
Phase 2
GSK-101
Human Epidermal Growth Factor Receptor 2 Low Breast Cance…
$GSK
GSK plc
Phase 2
GSK-4382276A
Seasonal Influenza
$GSK
GSK plc
Phase 2
GSK-5536522
Influenza A Virus, H5N1 Subtype Infections
$GSK
GSK plc
Phase 1
← prev
page 101 of 271
next →
Pain
89
Neurology
1
GT-01
Obesity
Gila Therapeutics Inc
Phase 1
GTB-3650
Myelodysplastic Syndrome (Preleukemia)
$GTBP
GT Biopharma, Inc.
Phase 1
GTB-5550
Epithelial Ovarian Cancer
$GTBP
GT Biopharma, Inc.
Preclinical
GTC-3295
Alzheimer's Disease
Gismo Therapeutics Inc
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE
no indication
RB HLTH
GUANFACINE
GUANFACINE
no indication
UNICHEM
Phase 2
GV-200251
Cervical Cancer
GV20 Therapeutics LLC
Preclinical
GW-01
Unspecified Cancer
Groovy Medicine Inc
Preclinical
GXC-301
Lafora Disease (Unverricht Disease)
Genixcure Inc
Preclinical
GXV-002
Pulmonary Arterial Hypertension
GEXVal Inc
Phase 1
Gallium Maltolate
Recurrent Glioblastoma Multiforme (GBM)
$KMCM
Titan Holdings Corp.
Marketed
Gasport
Famotidine
Corrosive Esophagitis (Erosive Esophagitis)
Sagent Pharmaceuticals Inc
Preclinical
Gene Therapies to Activate NAGLU for Mucopolysaccharidosis Type IIIB
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )
Neurogt Inc
Preclinical
Gene Therapy Product
Chemotherapy Induced Peripheral Neuropathy
Navega Therapeutics Inc
Preclinical
Gene Therapy for Alpha-Mannosidosis
Alpha-Mannosidosis
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Preclinical
Gene Therapy for Arginase 1 Deficiency
Hyperargininemia (Arginase I Deficiency)
UCLA Health System
Preclinical
Gene Therapy for Bone Fracture
Bone Fracture
Cedars-Sinai Medical Center
Preclinical
Gene Therapy for Branched-Chain 2-Ketoacid Dehydrogenase Deficiency
Maple Syrup Urine Disease
Clinic for Special Children
Preclinical
Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2C/R5
Limb-Girdle Muscular Dystrophy
Evolyra Therapeutics
Phase 2
Gene Therapy to Activate Artemis for Severe Combined Immune Deficiency
Severe Combined Immune Deficiency (SCID)
University of California San Francisco
Preclinical
Gene Therapy to Activate CD40LG for Genetic Disorders
no indication
University of California Los Angeles
Preclinical
Gene Therapy to Activate FOXP3 for Immune Dysregulation Polyendocrinopathy X-linked (IPEX) Syndrome
no indication
ImmunoVec Inc
Phase 2
Gene Therapy to Activate IL-2 Gamma Receptor for SCID-X1
X-Linked SCID
Boston Children's Hospital
Preclinical
Gene Therapy to Activate PCCA for Propionic Acidemia
Propionic Acidemia
National Institutes of Health
Phase 2
Gene Therapy to Activate Retinoschisin for X-Linked Retinoschisis
Retinal Degeneration
National Eye Institute
Preclinical
Gene Therapy to Activate gp91phox for Chronic Granulomatous Disease
Chronic Granulomatous Disease
ImmunoVec Inc
Preclinical
Gene Therapy to Target BCMA and CS1 for Multiple Myeloma
Multiple Myeloma (Kahler Disease)
University of California Los Angeles
